In short: Buffalo Funds (Mid Cap Growth Fund): "a leading fertility and family-building benefits management provider for self-insured employers," with "best-in-class fertility outcomes" and demographic support from "the societal trend towards later-in-life pregnancies in developed countries." The financial profile is the second half of the pitch: "an asset-light, cash-generative business model along with strong net-cash balance sheet, undemanding valuation multiple, and… rapidly shrinking the share count through repurchases." Earnings beat in the quarter and the stock outperformed, but it "remained a compelling investment opportunity."
Progyny manages fertility benefits for large employers that pay their own healthcare costs. Employees get access to a curated network of clinics; the employer gets better outcomes and, because treatment works more often, fewer repeat cycles.
Buffalo's case has two halves. The demand side is demographic and slow-moving: people in wealthy countries keep having children later, which increases the need for fertility treatment regardless of the economy. The financial side is that Progyny needs almost no capital to grow, holds more cash than debt, trades on an undemanding multiple, and is buying back its own shares quickly enough to shrink the share count meaningfully.
Full passage: premium transcript (PDF).
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.